The CRISPR System and Cancer Immunotherapy Biomarkers
Vitaly Balana, Jianbin Wanga b✉
- aRefuge Biotechnologies Inc., Menlo Park, CA, USA
- bRefuge Biotechnologies Inc., Menlo Park, CA, USA. james.wang@refugebiotech.com
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Recent advances in cancer immunotherapy have shed new light on the possibility to cure most, if not all, cancer patients with further development of various treatment options. The emergency of a new genome editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR) technology, revolutionized the biomedical research field. We envision application of the CRISPR technology in cancer research, diagnosis, and therapy will markedly speed up the development of new treatment options for cancer patients. The CRISPR system and its applications in biomedical research will be discussed with an emphasis on cancer immunotherapy and biomarker development.
TL;DRThe CRISPR system and its applications in biomedical research will be discussed with an emphasis on cancer immunotherapy and biomarker development and application of the technology in cancer research, diagnosis, and therapy will markedly speed up the development of new treatment options for cancer patients. (Semantic Scholar)